BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jung YS, Han M, Park S, Kim WH, Cheon JH. Cancer Risk in the Early Stages of Inflammatory Bowel Disease in Korean Patients: A Nationwide Population-based Study. J Crohns Colitis 2017;11:954-62. [PMID: 28333358 DOI: 10.1093/ecco-jcc/jjx040] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Jung YS, Han M, Park S, Cheon JH. Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn's Disease. Gut Liver 2021;15:92-9. [PMID: 32839359 DOI: 10.5009/gnl19377] [Reference Citation Analysis]
2 Cao L. Assessment of thyroid cancer risk in more than 334,000 patients with inflammatory bowel disease: a case-control study and a meta-analysis. World J Surg Oncol 2018;16:182. [PMID: 30200972 DOI: 10.1186/s12957-018-1485-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Barnhoorn MC, Van Halteren AGS, Van Pel M, Molendijk I, Struijk AC, Jansen PM, Verspaget HW, Dijkstra G, Oosten LEM, Van der Meulen-de Jong AE. Lymphoproliferative Disease in the Rectum 4 Years After Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report. J Crohns Colitis 2019;13:807-11. [PMID: 30561580 DOI: 10.1093/ecco-jcc/jjy220] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
4 Haddad A, Al-Sabbagh MQ, Al-Ani H, Siyam AM, Aborajooh E, Iwata T, Kimura S, Shariat SF, Abufaraj M. Inflammatory bowel disease and prostate cancer risk: A systematic review. Arab J Urol 2020;18:207-12. [PMID: 33312730 DOI: 10.1080/2090598X.2020.1761674] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Montenegro ML, Corral JE, Lukens FJ, Ji B, Kröner PT, Farraye FA, Bi Y. Pancreatic Disorders in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021. [PMID: 33625614 DOI: 10.1007/s10620-021-06899-2] [Reference Citation Analysis]
6 Park J, Cheon JH. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease. Gut Liver 2018;12:623-32. [PMID: 29788675 DOI: 10.5009/gnl17462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
7 Shah SC, Itzkowitz SH. Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology 2021:S0016-5085(21)03707-0. [PMID: 34757143 DOI: 10.1053/j.gastro.2021.10.035] [Reference Citation Analysis]
8 Romano L, Granata L, Fusco F, Napolitano L, Cerbone R, Priadko K, Sciorio C, Mirone V, Romano M. Sexual Dysfunction in Patients With Chronic Gastrointestinal and Liver Diseases: A neglected Issue. Sex Med Rev 2021:S2050-0521(21)00039-1. [PMID: 34353738 DOI: 10.1016/j.sxmr.2021.02.002] [Reference Citation Analysis]
9 Massironi S, Fanetti I, Viganò C, Pirola L, Fichera M, Cristoferi L, Capurso G, Invernizzi P, Danese S. Systematic review-pancreatic involvement in inflammatory bowel disease. Aliment Pharmacol Ther 2022;55:1478-91. [PMID: 35505465 DOI: 10.1111/apt.16949] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Moll F, Walter M, Rezende F, Helfinger V, Vasconez E, De Oliveira T, Greten FR, Olesch C, Weigert A, Radeke HH, Schröder K. NoxO1 Controls Proliferation of Colon Epithelial Cells. Front Immunol 2018;9:973. [PMID: 29867954 DOI: 10.3389/fimmu.2018.00973] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
11 Lo B, Zhao M, Vind I, Burisch J. The Risk of Extraintestinal Cancer in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Cohort Studies. Clinical Gastroenterology and Hepatology 2021;19:1117-1138.e19. [DOI: 10.1016/j.cgh.2020.08.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Meyers TJ, Weiner AB, Graff RE, Desai AS, Cooley LF, Catalona WJ, Hanauer SB, Wu JD, Schaeffer EM, Abdulkadir SA, Kundu SD, Witte JS. Association between inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based study. Int J Cancer 2020;147:2735-42. [PMID: 32399975 DOI: 10.1002/ijc.33048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
13 Nadeem MS, Kumar V, Al-abbasi FA, Kamal MA, Anwar F. Risk of colorectal cancer in inflammatory bowel diseases. Seminars in Cancer Biology 2020;64:51-60. [DOI: 10.1016/j.semcancer.2019.05.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
14 Keuchel M, Kurniawan N, Baltes P. Small bowel ulcers: when is it not inflammatory bowel disease ? Curr Opin Gastroenterol 2019;35:213-22. [PMID: 30865040 DOI: 10.1097/MOG.0000000000000522] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Kim H, Kim JH, Lee JK, Kang DR, Kim SY, Kim HS, Kim HM. Incident Crohn's Disease as a Risk Factor for Colorectal Cancer in the First 10 Years after Diagnosis: A Nationwide Population-Based Study. J Clin Med 2021;10:4663. [PMID: 34682786 DOI: 10.3390/jcm10204663] [Reference Citation Analysis]
16 Hammami MB, Mahadevan U. Men With Inflammatory Bowel Disease: Sexual Function, Fertility, Medication Safety, and Prostate Cancer. Am J Gastroenterol. 2020;115:526-534. [PMID: 32022719 DOI: 10.14309/ajg.0000000000000515] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
17 Lee CK, Ha HJ, Oh SJ, Kim JW, Lee JK, Kim HS, Yoon SM, Kang SB, Kim ES, Kim TO, Na SY, Lee J, Kim SW, Koo HS, Park BK, Lee HH, Kim ES, Park JJ, Kwak MS, Cha JM, Ye BD, Choi CH, Kim HJ. Nationwide validation study of diagnostic algorithms for inflammatory bowel disease in Korean National Health Insurance Service database. J Gastroenterol Hepatol 2020;35:760-8. [PMID: 31498502 DOI: 10.1111/jgh.14855] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
18 Jones JL, Tse F, Carroll MW, deBruyn JC, McNeil SA, Pham-Huy A, Seow CH, Barrett LL, Bessissow T, Carman N, Melmed GY, Vanderkooi OG, Marshall JK, Benchimol EI. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines. Gastroenterology 2021;161:681-700. [PMID: 34334167 DOI: 10.1053/j.gastro.2021.04.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chin YH, Jain SR, Lee MH, Ng CH, Lin SY, Mai AS, Muthiah MD, Foo FJ, Sundar R, Ong DEH, Leow WQ, Leong R, Chan WPW. Small bowel adenocarcinoma in Crohn's disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes. Int J Colorectal Dis 2021. [PMID: 34704127 DOI: 10.1007/s00384-021-04050-1] [Reference Citation Analysis]
20 Manjili SH, Isbell M, Ghochaghi N, Perkinson T, Manjili MH. Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse. Semin Cancer Biol 2021:S1044-579X(21)00073-0. [PMID: 33785450 DOI: 10.1016/j.semcancer.2021.03.023] [Reference Citation Analysis]
21 Shen Q, Huang Z, Yao J, Jin Y. Extracellular vesicles-mediated interaction within intestinal microenvironment in inflammatory bowel disease. Journal of Advanced Research 2021. [DOI: 10.1016/j.jare.2021.07.002] [Reference Citation Analysis]
22 Born J, Hendricks A, Hauser C, Egberts JH, Becker T, Röder C, Sebens S. Detection of Marker Associated with CTC in Colorectal Cancer in Mononuclear Cells of Patients with Benign Inflammatory Intestinal Diseases. Cancers (Basel) 2021;14:47. [PMID: 35008210 DOI: 10.3390/cancers14010047] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol. 2020;35:380-389. [PMID: 31596960 DOI: 10.1111/jgh.14872] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 14.7] [Reference Citation Analysis]
24 Jung YS, Han M, Park S, Cheon JH. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study. Dig Dis Sci 2020;65:1436-44. [PMID: 31677070 DOI: 10.1007/s10620-019-05867-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Oh HJ, Lee HA, Moon CM, Ryu DR. Incidence risk of various types of digestive cancers in patients with pre-dialytic chronic kidney disease: A nationwide population-based cohort study. PLoS One 2018;13:e0207756. [PMID: 30458033 DOI: 10.1371/journal.pone.0207756] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
26 Jung YS, Han M, Park S, Cheon JH. Impact of early anti-TNF use on clinical outcomes in Crohn's disease: a nationwide population-based study. Korean J Intern Med 2020;35:1104-13. [PMID: 32306709 DOI: 10.3904/kjim.2020.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Gong C, Xu R, Zou P, Zhang Y, Wang X. Inflammatory bowel disease and risk of breast cancer: a meta-analysis of cohort studies. Eur J Cancer Prev 2022;31:54-63. [PMID: 34871199 DOI: 10.1097/CEJ.0000000000000667] [Reference Citation Analysis]
28 Zheng R, Ma J, Wang D, Dong W, Wang S, Liu T, Xie R, Liu L, Wang B, Cao H. Chemopreventive Effects of Silibinin on Colitis-Associated Tumorigenesis by Inhibiting IL-6/STAT3 Signaling Pathway. Mediators Inflamm 2018;2018:1562010. [PMID: 30498394 DOI: 10.1155/2018/1562010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
29 Jones JL, Tse F, Carroll MW, deBruyn JC, McNeil SA, Pham-Huy A, Seow CH, Barrett LL, Bessissow T, Carman N, Melmed GY, Vanderkooi OG, Marshall JK, Benchimol EI. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines. J Can Assoc Gastroenterol 2021;4:e72-91. [PMID: 34476339 DOI: 10.1093/jcag/gwab016] [Reference Citation Analysis]
30 Caviglia GP, Martini G, Armandi A, Rosso C, Vernero M, Bugianesi E, Astegiano M, Saracco GM, Ribaldone DG. Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease. J Clin Med 2021;10:3257. [PMID: 34362041 DOI: 10.3390/jcm10153257] [Reference Citation Analysis]
31 Wu S, Xie S, Yuan C, Yang Z, Liu S, Zhang Q, Sun F, Wu J, Zhan S, Zhu S, Zhang S. Inflammatory Bowel Disease and Long-term Risk of Cancer: A Prospective Cohort Study Among Half a Million Adults in UK Biobank. Inflamm Bowel Dis 2022:izac096. [PMID: 35639937 DOI: 10.1093/ibd/izac096] [Reference Citation Analysis]
32 Dore MP, Fanciulli G, Manca A, Cocco V, Nieddu A, Murgia M, Pes GM. Clinically relevant thyroid disorders and inflammatory bowel disease are inversely related: a retrospective case-control study. Scand J Gastroenterol 2021;56:171-6. [PMID: 33327797 DOI: 10.1080/00365521.2020.1861323] [Reference Citation Analysis]
33 Kim HM, Kim JH, Lee JK, Kang DR, Kim H, Kim SY, Kim HS. Age- and sex-specific risk of colorectal cancer in incident ulcerative colitis during the first 10 years after diagnosis: a nationwide population-based study. Scand J Gastroenterol 2021;:1-7. [PMID: 34376117 DOI: 10.1080/00365521.2021.1958370] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Hamanaka S, Nakagawa T, Ota S, Iida M, Ohta Y, Isshiki Y, Kasamatsu S, Ishigami H, Taida T, Okimoto K, Saito K, Maruoka D, Matsumura T, Ohwada C, Takeuchi M, Sakaida E, Arai M, Katsuno T, Nakaseko C, Nakatani Y, Kato N. Immunomodulator-associated Epstein-Barr virus-positive mucocutaneous ulcer in a patient with refractory Crohn's disease. Clin J Gastroenterol 2019;12:330-5. [PMID: 30903514 DOI: 10.1007/s12328-019-00952-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
35 Cui Y, Jin X, Zhang H, Liu L. Association between inflammatory bowel disease and risk of abnormalities of uterine cervix. J Obstet Gynaecol Res 2021;47:4030-6. [PMID: 34528331 DOI: 10.1111/jog.14992] [Reference Citation Analysis]
36 Chang X, Wang SL, Zhao SB, Shi YH, Pan P, Gu L, Yao J, Li ZS, Bai Y. Extracellular Vesicles with Possible Roles in Gut Intestinal Tract Homeostasis and IBD. Mediators Inflamm 2020;2020:1945832. [PMID: 32410847 DOI: 10.1155/2020/1945832] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
37 Han M, Jung YS, Cheon JH, Park S. Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases. J Gastroenterol Hepatol 2019;34:1166-74. [PMID: 30672608 DOI: 10.1111/jgh.14609] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
38 Burns JA, Weiner AB, Kundu S. Reply to Zeynep G. Gul, Alberto Martini, and Carl A. Olsson's Letter to the Editor re: Jacob A. Burns, Adam B. Weiner, William J. Catalona, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol 2019;75:846-52. Eur Urol 2019;76:e99-e100. [PMID: 31151679 DOI: 10.1016/j.eururo.2019.05.027] [Reference Citation Analysis]
39 Taborelli M, Sozzi M, Del Zotto S, Toffolutti F, Montico M, Zanier L, Serraino D. Risk of intestinal and extra-intestinal cancers in patients with inflammatory bowel diseases: A population-based cohort study in northeastern Italy. PLoS One 2020;15:e0235142. [PMID: 32574216 DOI: 10.1371/journal.pone.0235142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 He MM, Lo CH, Wang K, Polychronidis G, Wang L, Zhong R, Knudsen MD, Fang Z, Song M. Immune-Mediated Diseases Associated With Cancer Risks. JAMA Oncol 2021. [PMID: 34854871 DOI: 10.1001/jamaoncol.2021.5680] [Reference Citation Analysis]
41 Wan Q, Zhao R, Xia L, Wu Y, Zhou Y, Wang Y, Cui Y, Shen X, Wu XT. Inflammatory bowel disease and risk of gastric, small bowel and colorectal cancer: a meta-analysis of 26 observational studies. J Cancer Res Clin Oncol 2021;147:1077-87. [PMID: 33433655 DOI: 10.1007/s00432-020-03496-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Han M, Jung YS, Cheon JH, Park S. Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study. Yonsei Med J 2020;61:382-90. [PMID: 32390361 DOI: 10.3349/ymj.2020.61.5.382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Zeng X, Zhang P, Xiao H, Wu X, Liu W, He J, Gao J, Wang G, Shuai X, Tao K. Clinicopathological features and prognosis of intestinal hepatoid adenocarcinoma: evaluation of a pooled case series. Oncotarget 2018;9:2715-25. [PMID: 29416804 DOI: 10.18632/oncotarget.23595] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
44 Choi YY, Lee JK, Kim HS, Kim DW, Kim HM, Kang DR. Medications and the Risk of Colorectal Cancer in Patients with Inflammatory Bowel Diseases: Use of the Landmark Method. Yonsei Med J 2021;62:997-1004. [PMID: 34672133 DOI: 10.3349/ymj.2021.62.11.997] [Reference Citation Analysis]
45 Everhov ÅH, Erichsen R, Sachs MC, Pedersen L, Halfvarson J, Askling J, Ekbom A, Ludvigsson JF, Sørensen HT, Olén O. Inflammatory bowel disease and pancreatic cancer: a Scandinavian register-based cohort study 1969-2017. Aliment Pharmacol Ther 2020;52:143-54. [PMID: 32412143 DOI: 10.1111/apt.15785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
46 Na SJ, Kang MJ, Yu DS, Han K, Lee JH, Park YG, Lee YB. Cancer risk in patients with Behçet disease: A nationwide population-based dynamic cohort study from Korea. Journal of the American Academy of Dermatology 2018;78:464-470.e2. [DOI: 10.1016/j.jaad.2017.09.035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
47 Ge Y, Shi Q, Yao W, Cheng Y, Ma G. The association between inflammatory bowel disease and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis 2020;23:53-8. [PMID: 31591455 DOI: 10.1038/s41391-019-0177-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
48 Soh H, Chun J, Han K, Park S, Choi G, Kim J, Lee J, Im JP, Kim JS. Increased Risk of Herpes Zoster in Young and Metabolically Healthy Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study. Gut Liver. 2019;13:333-341. [PMID: 30602222 DOI: 10.5009/gnl18304] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
49 Iida T, Wagatsuma K, Hirayama D, Yokoyama Y, Nakase H. The Etiology of Pancreatic Manifestations in Patients with Inflammatory Bowel Disease. J Clin Med. 2019;8:pii: E916. [PMID: 31247968 DOI: 10.3390/jcm8070916] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
50 Chen M, Yuan C, Xu T. An increase in prostate cancer diagnosis during inflammatory bowel disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2020;44:302-9. [PMID: 31447293 DOI: 10.1016/j.clinre.2019.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
51 Zhou Q, Shen ZF, Wu BS, Xu CB, He ZQ, Chen T, Shang HT, Xie CF, Huang SY, Chen YG, Chen HB, Han ST. Risk of Colorectal Cancer in Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2019;2019:5363261. [PMID: 31781191 DOI: 10.1155/2019/5363261] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
52 Han M, Jung YS, Cheon JH, Park S. Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study. Yonsei Med J 2020;61:48-55. [PMID: 31887799 DOI: 10.3349/ymj.2020.61.1.48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Zhang C, Liu S, Peng L, Wu J, Zeng X, Lu Y, Shen H, Luo D. Does inflammatory bowel disease increase the risk of lower urinary tract tumors: a meta-analysis. Transl Androl Urol 2021;10:164-73. [PMID: 33532306 DOI: 10.21037/tau-20-1020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
54 Feng D, Bai Y, Liu S, Yang Y, Han P, Wei W. Risk of renal cancer in patients with inflammatory bowel disease: A pooled analysis of population-based studies. Urol Oncol 2021;39:93-9. [PMID: 33214029 DOI: 10.1016/j.urolonc.2020.10.078] [Reference Citation Analysis]
55 Yang Q, Ouyang J, Pi D, Feng L, Yang J. Malassezia in Inflammatory Bowel Disease: Accomplice of Evoking Tumorigenesis. Front Immunol 2022;13:846469. [DOI: 10.3389/fimmu.2022.846469] [Reference Citation Analysis]
56 Yu J, Refsum E, Helsingen LM, Folseraas T, Ploner A, Wieszczy P, Barua I, Jodal HC, Melum E, Løberg M, Blom J, Bretthauer M, Adami HO, Kalager M, Ye W. Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study. United European Gastroenterol J 2022. [PMID: 35107865 DOI: 10.1002/ueg2.12204] [Reference Citation Analysis]
57 Burns JA, Weiner AB, Catalona WJ, Li EV, Schaeffer EM, Hanauer SB, Strong S, Burns J, Hussain MHA, Kundu SD. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol 2019;75:846-52. [PMID: 30528221 DOI: 10.1016/j.eururo.2018.11.039] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
58 Carli E, Caviglia GP, Pellicano R, Fagoonee S, Rizza S, Astegiano M, Saracco GM, Ribaldone DG. Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis. Medicina (Kaunas) 2020;56:E285. [PMID: 32545154 DOI: 10.3390/medicina56060285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Zhao R, Wan QY, Wu Y, Wang Y, Cui YP, Shen X, Wu XT. Crohn's disease instead of UC might increase the risk of small bowel cancer. Gut 2021;70:809-10. [PMID: 32665339 DOI: 10.1136/gutjnl-2020-322201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Yang C, Huang J, Huang X, Huang S, Cheng J, Liao W, Chen X, Wang X, Dai S. Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis. J Crohns Colitis 2018;12:1042-52. [PMID: 29762681 DOI: 10.1093/ecco-jcc/jjy065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
61 Mala A, Foteinogiannopoulou K, Koutroubakis IE. Solid extraintestinal malignancies in patients with inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(12): 1956-1980 [DOI: 10.4251/wjgo.v13.i12.1956] [Reference Citation Analysis]
62 Geng Z, Geng Q. Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis. Front Surg 2021;8:636791. [PMID: 34124132 DOI: 10.3389/fsurg.2021.636791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Feng D, Yang Y, Wang Z, Wei W, Li L. Inflammatory bowel disease and risk of urinary cancers: a systematic review and pooled analysis of population-based studies. Transl Androl Urol 2021;10:1332-41. [PMID: 33850767 DOI: 10.21037/tau-20-1358] [Reference Citation Analysis]